Curative Biotechnology, Inc. (CUBT)
| Market Cap | 7.15M +14.5% |
| Revenue (ttm) | n/a |
| Net Income | -2.84M |
| EPS | -0.42 |
| Shares Out | 7.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 634 |
| Open | 0.976 |
| Previous Close | 1.000 |
| Day's Range | 0.976 - 1.000 |
| 52-Week Range | 0.031 - 1.990 |
| Beta | 1.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Curative Biotechnology
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licen... [Read more]
Financial Performance
Financial StatementsNews
Curative Biotechnology, Inc. Issues Letter to Shareholders
Company Reviews Significant Ophthalmology, Intellectual Property and Translational Development Milestones Achieved Over the Past Year Palm Beach Gardens, FL, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Curativ...
Curative Biotechnology Announces Reverse Stock Split and Strategic Progress Toward OTCQB Uplisting
Strengthening Capital Structure and Advancing Clinical Development Strategy Palm Beach Gardens, FL, March 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBTD) (“Curative” or the “Com...
Curative Biotech announces Canadian patent allowance
Curative Biotech (CUBT)nology announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian Patent Application No. 3,151,011, entitled “Druggable Target to Tre...
Curative Biotechnology Announces Canadian Patent Allowance
“Druggable Target to Treat Retinal Degeneration” Palm Beach Gardens, FL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a company developing ...
Curative Biotechnology, Inc. Announces Letter to Shareholders
Strategic Update and New Path to Value Creation Palm Beach Gardens, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-s...
Curative Biotechnology, Inc. Engages Golden Eagle Capital Advisors, Inc. as Exclusive Agent and Strategic Advisor
Palm Beach Gardens, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatme...
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focus...
Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors
Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange
Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions
Appoints Paul Mich aels Co-CEO of Parent and CEO of Subsidiary Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a develo...
Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation
Topical Administration Capable of Delivering Metformin to Choroid, RPE, and Retin a Boca Raton, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the ...
Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for ...
Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange
Boca Raton, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for...
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors
Appointment of Independent Director Builds Upon Biotech Expertise
Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors
Appointment of Independent Director Adds to Financial Expertise on Board BOCA RATON, Fla. , May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), ...
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors
Appointment of Independent Director Adds to Financial Expertise on Board
Curative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Formulations for Treatment of Macular Degeneration
National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA) BOCA RATON, Fla. , May 3, 2022 /PRNewswire/ -- Curative Biotechn...
Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulations for Treatment of Macular Degeneration
National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA)
Curative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration
BOCA RATON, Fla. , March 21, 2022 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company focused on novel treatments for rare di...
Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration
Emily Y. Chew, M.D. of the National Eye Institute Assigned Principal Investigator
[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
Company's First I n -license Pipeline P roduct to E nter P re- clinical S tudies
CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
Company's First I n -license Pipeline P roduct to E nter P re- clinical S tudies
CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients , Late-Stage Rabies Therapeutic and Age-related Macular Degeneration
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine
BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the Company has reached agreement with Mid-Atlantic B...
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board
Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Exper tise in Neurobiology
Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee
Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for r...